PMID- 27894270
OWN - NLM
STAT- MEDLINE
DCOM- 20170612
LR  - 20181202
IS  - 1471-2334 (Electronic)
IS  - 1471-2334 (Linking)
VI  - 16
IP  - 1
DP  - 2016 Nov 29
TI  - Evaluation of tolerability with the co-formulation elvitegravir, cobicistat, 
      emtricitabine, and tenofovir disoproxil fumarate for post-HIV exposure 
      prophylaxis.
PG  - 718
LID - 718
AB  - BACKGROUND: The preferred regimen for HIV post-exposure prophylaxis (PEP) is 
      based mainly on safety and tolerability because it is given to immunocompetent 
      people without HIV infection for a limited time (28 days). The frequency of 
      adverse events (AEs) may be > 60%. Although AEs are generally not severe, they 
      can lead to lack of adherence and failure to complete the regimen. We evaluated 
      the co-formulation elvitegravir, cobicistat, emtricitabine, and tenofovir 
      disoproxil fumarate (Stribild((R))) prescribed as one pill taken once daily for HIV 
      PEP in terms of tolerability and adherence. METHODS: This was a prospective 
      cohort study conducted in one hospital in Paris (April to December 2015. Each 
      participant receiving the PEP treatment 
      (FTC-150 mg/TDF-245 mg/elvitegravir-200 mg/cobicistat 150 mg once daily) at the 
      pharmacy of the hospital were recruited consecutively. A clinical visit was 
      planned at 8 weeks after sexual exposure. Reminders were sent to participants who 
      missed the appointment. A standardized questionnaire was administered to evaluate 
      completeness and tolerability at week 8. RESULTS: Overall, 284 participants (86% 
      men; 80% MSM; median age 30 years) were prescribed Stribild((R)); 50 stopped after 
      reassessment of risk. Among 234 participants who effectively received PEP, 215 
      (92%) completed 28 days of PEP with only three who switched from Stribild((R)) to 
      another PEP because of side effects. More than 60% of participants reported at 
      least one AE, which were mild to moderate. Fatigue, central neurological and 
      abdominal side effects were the most frequently reported. CONCLUSIONS: 
      Stribild((R)) seems to be a good option for HIV PEP due to the easiness of use, the 
      side effects profile and the high completion rate.
FAU - Valin, Nadia
AU  - Valin N
AUID- ORCID: 0000-0001-5706-1195
AD  - Hopital Saint-Antoine, Service des Maladies Infectieuses et Tropicales, 184 rue 
      du Faubourg Saint-Antoine, F75571, Paris Cedex 12, France. nadia.valin@aphp.fr.
FAU - Fonquernie, Laurent
AU  - Fonquernie L
AD  - Hopital Saint-Antoine, Service des Maladies Infectieuses et Tropicales, 184 rue 
      du Faubourg Saint-Antoine, F75571, Paris Cedex 12, France.
FAU - Daguenel, Anne
AU  - Daguenel A
AD  - Hopital Saint-Antoine, Service Pharmacie, 184 rue du Faubourg Saint-Antoine, 
      F75571, Paris Cedex 12, France.
FAU - Campa, Pauline
AU  - Campa P
AD  - Hopital Saint-Antoine, Service des Maladies Infectieuses et Tropicales, 184 rue 
      du Faubourg Saint-Antoine, F75571, Paris Cedex 12, France.
FAU - Anthony, Theresita
AU  - Anthony T
AD  - Hopital Saint-Antoine, Service des Maladies Infectieuses et Tropicales, 184 rue 
      du Faubourg Saint-Antoine, F75571, Paris Cedex 12, France.
FAU - Guiguet, Marguerite
AU  - Guiguet M
AD  - Sorbonne Universites, UPMC Univ Paris 06, INSERM, Institut Pierre Louis 
      d'Epidemiologie et de Sante Publique (IPLESP UMRS 1136), F75013, Paris, France.
FAU - Girard, Pierre Marie
AU  - Girard PM
AD  - Hopital Saint-Antoine, Service des Maladies Infectieuses et Tropicales, 184 rue 
      du Faubourg Saint-Antoine, F75571, Paris Cedex 12, France.
AD  - Sorbonne Universites, UPMC Univ Paris 06, INSERM, Institut Pierre Louis 
      d'Epidemiologie et de Sante Publique (IPLESP UMRS 1136), F75013, Paris, France.
FAU - Meyohas, Marie Caroline
AU  - Meyohas MC
AD  - Hopital Saint-Antoine, Service des Maladies Infectieuses et Tropicales, 184 rue 
      du Faubourg Saint-Antoine, F75571, Paris Cedex 12, France.
AD  - Sorbonne Universites, UPMC Univ Paris 06, F75005, Paris, France.
LA  - eng
PT  - Journal Article
DEP - 20161129
PL  - England
TA  - BMC Infect Dis
JT  - BMC infectious diseases
JID - 100968551
RN  - 0 (Anti-HIV Agents)
RN  - 0 (Drug Combinations)
RN  - 0 (Elvitegravir, Cobicistat, Emtricitabine, Tenofovir Disoproxil Fumarate Drug 
      Combination)
RN  - LW2E03M5PG (Cobicistat)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Anti-HIV Agents/administration & dosage/*adverse effects/*therapeutic use
MH  - Cobicistat
MH  - Drug Combinations
MH  - Elvitegravir, Cobicistat, Emtricitabine, Tenofovir Disoproxil Fumarate Drug 
      Combination/administration & dosage/adverse effects/*therapeutic use
MH  - Female
MH  - HIV Infections/drug therapy/*prevention & control
MH  - Homosexuality, Male
MH  - Humans
MH  - Male
MH  - Medication Adherence
MH  - Middle Aged
MH  - Paris
MH  - Post-Exposure Prophylaxis/*methods
MH  - Prospective Studies
MH  - Sexual Behavior
MH  - Young Adult
PMC - PMC5127047
EDAT- 2016/11/30 06:00
MHDA- 2017/06/13 06:00
PMCR- 2016/11/29
CRDT- 2016/11/30 06:00
PHST- 2016/08/21 00:00 [received]
PHST- 2016/11/22 00:00 [accepted]
PHST- 2016/11/30 06:00 [entrez]
PHST- 2016/11/30 06:00 [pubmed]
PHST- 2017/06/13 06:00 [medline]
PHST- 2016/11/29 00:00 [pmc-release]
AID - 10.1186/s12879-016-2056-3 [pii]
AID - 2056 [pii]
AID - 10.1186/s12879-016-2056-3 [doi]
PST - epublish
SO  - BMC Infect Dis. 2016 Nov 29;16(1):718. doi: 10.1186/s12879-016-2056-3.